Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,479
  • Shares Outstanding, K 24,293
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,010 K
  • EBIT $ -15 M
  • EBITDA $ -14 M
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Options Overview Details

View History
  • Implied Volatility 296.35% (-20.67%)
  • Historical Volatility 73.70%
  • IV Percentile 21%
  • IV Rank 19.63%
  • IV High 1,229.17% on 03/19/25
  • IV Low 68.53% on 09/18/25
  • Expected Move (DTE 14) 1.2750 (109.91%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 369
  • Volume Avg (30-Day) 447
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 3,233
  • Open Int (30-Day) 3,171
  • Expected Range 0.0000 to 2.4350

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +52.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8313 +39.54%
on 11/21/25
1.8100 -35.91%
on 11/24/25
+0.1300 (+12.62%)
since 11/04/25
3-Month
0.8313 +39.54%
on 11/21/25
1.8100 -35.91%
on 11/24/25
+0.0900 (+8.41%)
since 09/04/25
52-Week
0.8313 +39.54%
on 11/21/25
2.1000 -44.76%
on 08/15/25
-0.1400 (-10.77%)
since 12/04/24

Most Recent Stories

More News
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors

Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation

ENLV : 1.1600 (+6.42%)
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / October 3, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Lantern Pharma, Inc. (Nasdaq:LTRN) on the RedChip Small Stocks,...

ENLV : 1.1600 (+6.42%)
LTRN : 3.77 (+6.50%)
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / September 19, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip...

ENLV : 1.1600 (+6.42%)
SXTP : 0.9801 (-3.91%)
Home Sales Stateside, Canada GDP Due Next Week

Monday U.S. Economic Lookahead New home sales (July) Featured Earnings PDD ...

NVDA : 183.38 (+2.11%)
BEKE : 16.80 (+1.02%)
FRO : 23.24 (-1.53%)
CRWD : 513.12 (-2.11%)
SNOW : 234.77 (-11.41%)
ADSK : 305.85 (-0.45%)
MDB : 396.73 (-2.27%)
OKTA : 85.90 (-0.51%)
HEI : 315.64 (+2.00%)
NSSC : 40.93 (-0.22%)
JKS : 24.80 (+2.82%)
ENLV : 1.1600 (+6.42%)
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / June 13, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics (NASDAQ:ENLV) and Foremost Clean Energy (Nasdaq:FMST) on the RedChip Small Stocks, Big Moneyâ„¢...

ENLV : 1.1600 (+6.42%)
FMST : 3.06 (+6.99%)
FAT.CN : 4.2900 (+7.52%)
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis

Unlock AI-powered insights for data-driven precision and real-time efficiency

ENLV : 1.1600 (+6.42%)
ASPI : 6.67 (+16.40%)
BFRG : 1.1500 (+5.50%)
NVA : 10.38 (+11.97%)
GRRR : 15.49 (+10.80%)
The Trump Effect: Crypto Diversification Accelerates Across Industries

Issued on behalf of Spearmint Resources Inc. VANCOUVER – USA News Group – With the upcoming inauguration of US President Re-Elect Donald Trump on the horizon, several businesses are diversifying...

MSTR : 186.01 (-1.26%)
TSLA : 454.53 (+1.74%)
ENLV : 1.1600 (+6.42%)
SPMTF : 0.0718 (+0.28%)
SPMT.CN : 0.0050 (-33.33%)
^BTCUSDT : 92,076.91 (-0.11%)
HOTH : 1.1900 (-0.83%)
^BTCUSD : 91,948.58 (-0.25%)
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and bioAffinity Technologies, Inc. (Nasdaq:BIAF) on the RedChip Small Stocks,...

ENLV : 1.1600 (+6.42%)
BIAF : 1.7200 (+9.55%)
Enlivex Therapeutics Ltd. Receives Approval for Phase I Trial of Allocetraâ„¢ in TMJ Osteoarthritis Patients

Enlivex Therapeutics received authorization for a Phase I trial of Allocetraâ„¢ for TMJ osteoarthritis in Israel.Quiver AI SummaryEnlivex Therapeutics Ltd. has received approval from the Israeli Ministry...

ENLV : 1.1600 (+6.42%)
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

NESS ZIONA, ISRAEL / ACCESSWIRE / November 26, 2024 / Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors...

ENLV : 1.1600 (+6.42%)

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.2533
1st Resistance Point 1.2067
Last Price 1.1600
1st Support Level 1.0867
2nd Support Level 1.0133
3rd Support Level 0.9667

See More

52-Week High 2.1000
Fibonacci 61.8% 1.6154
Fibonacci 50% 1.4656
Fibonacci 38.2% 1.3159
Last Price 1.1600
52-Week Low 0.8313

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar